Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
US Generics grew 5% to Rs. 467 Crores for the quarter
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Subscribe To Our Newsletter & Stay Updated